Drug intelligence / Profile preview

99mTc dextran 500 + patent blue V

Development stage: Unknown
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Subcutaneous, Peritumoral

Overview

A combination of a radiopharmaceutical (99mTc dextran 500) and a vital blue dye (patent blue V) used for sentinel lymph node detection and mapping, particularly in breast cancer surgery. The dual-tracer technique enhances visualization and identification of sentinel lymph nodes during surgical procedures.

Targets

MRC1 (Mannose Receptor C-type 1)

Beyond the preview

Go deeper on 99mTc dextran 500 + patent blue V.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 99mTc dextran 500 + patent blue V.

Explore the full profile